For the proposed application, Dr. Burridge’s lab will provide their expertise in validation of genetic variants as well as exploring the mechanisms of anthracycline-related cardiotoxicity using hiPSC-CMs. This work will involve generating hiPSC-CMs with knockouts of the genetic variants using CRISPR-Cas9, followed by SNP correction to confirm that the SNP was the effector. They will also assess the role of the genetic variants in generation of cardiotoxic metabolites, ROS levels, TNNT2 splicing as well as a variety of other methodologies to determine the mechanism of action of anthracyclines in inducing cardiotoxicity.
|Effective start/end date||9/1/18 → 8/31/25|
- University of Alabama at Birmingham (000519160-003//1R35CA220502-01A1)
- National Cancer Institute (000519160-003//1R35CA220502-01A1)